1Weiss R A. Gulliver's travels in HIVl and. Nature, 2001, 410: 963-967
2Stevenson M. HIV-1 Pathogenesis. Nature Med, 2003, 9: 853-860
3Cormier E G, Tran D N, Yukhayeva L, et al. Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes. J Virol, 2001, 75: 5541～5549
4Zhang W T, Canziani G, Plugariu C, et al. Conformation changes of gp120 in epitopes near the CCR5 binding site are induce by CD4 and a CD4 miniprotein mimetic. Biochemistry, 1999, 38: 9405～9416
5Kwong P D, Wyatt R, Robinson J, et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature, 1998, 393: 648～659
6Wyatt R, Kwong P D, Desjardins E, et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature, 1998, 393: 705～711
7Field C G, Lloyd D H, Macdonaid R L, et al. HBTU activation for automated Fmoc solid-phase peptide synthesis. Pept Res, 1991, 4: 95～101
10Tsamis F, Gavrilov S, Kajumo F, et al. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol, 2003, 77: 5201～5208
